Literature DB >> 28473361

Seizure induced by sudden cessation of pregabalin in a patient with chronic kidney disease.

Yang Timothy Du1,2, Anthony P Roberts1,2, David J Torpy1,2.   

Abstract

A middle-aged woman with diabetic nephropathy on pregabalin for neuropathic pain presented with a diarrhoeal illness. She was found to have acute on chronic renal impairment with an estimated glomerular filtration rate (eGFR) of 10 mL/min, and her usual 150 mg/day of pregabalin was abruptly ceased. Although renal recovery to her baseline of eGFR 15 mL/min was achieved within 3 days, her pregabalin was not restarted. She suffered a tonic-clonic seizure 4 days later, thought to be due to pregabalin withdrawal as there were no other likely causes identified. She suffered no further seizures on recommencement of pregabalin at a renally adjusted dose of 75 mg/day. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Contraindications and precautions; Endocrine system; Neurology (drugs and medicines); Renal system

Mesh:

Substances:

Year:  2017        PMID: 28473361      PMCID: PMC5747663          DOI: 10.1136/bcr-2016-219158

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.

Authors:  Siegfried Kasper; Celso Iglesias-García; Edward Schweizer; Jacquelyn Wilson; Sarah DuBrava; Rita Prieto; Verne W Pitman; Lloyd Knapp
Journal:  Int J Neuropsychopharmacol       Date:  2013-12-19       Impact factor: 5.176

2.  A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.

Authors:  Sofie Schwan; Anders Sundström; Elisabet Stjernberg; Ebba Hallberg; Pär Hallberg
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953

3.  Spasticity increases during pregabalin withdrawal.

Authors:  J J Braid; S G B Kirker; I J Baguley
Journal:  Brain Inj       Date:  2013       Impact factor: 2.311

4.  Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures.

Authors:  J A French; A R Kugler; J L Robbins; L E Knapp; E A Garofalo
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

5.  Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

Authors:  Julio Rosenstock; Michael Tuchman; Linda LaMoreaux; Uma Sharma
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

  5 in total
  1 in total

1.  Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review.

Authors:  Hayahito Ishikawa; Masahiro Takeshima; Hiroyasu Ishikawa; Naoko Ayabe; Hidenobu Ohta; Kazuo Mishima
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.